The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
See my post WBAFC , I am well aware of the CEO.
I was highlighting something entirely different , you either understand or you don't. Im not spelling it out on a public forum.
Kaeren , regarding ROQ , looks like Ajan Reginald (CEO) is there . I would not trust this fella .
Hi Karen hope your well ....bodes well ..sign ... signature
Anyone watching the placing that never was ROQ .. AR
Pattern bioscience ...Austin texas ...>....direction
As Kaeren has just pointed out this is just mere speculation. On my part it's to highlight the sheer undervaluation here, that for example a loss making diagnostics company that is cash-strapped and at most able to raise a few million in the coming months in return for a significant chunk of the company is valued at more than a third of what Novacyt is currently.
And also how Novacyt could partner and take a significant interest (less risk, time and energy of TO) for petty cash.
Companies with a healthy profit cost substantially more WBAFC. From reading about what GDR have in the pipeline ( stroke) they look very much like a company that will be profitable going forwards but have a cash crisis right now.
Nothing to say NCYT are remotely interested , I just raised it as it is the sort of opportunity we are in the position to avail of.
The duration for an outright T/O clashes with court case and therefore I don't see that as feasible , however a % is certainly something they could proceed with if they so desired.
HC , should Novacyt really be going after companies like GDR that are not profit making ? I think Novacyt should really be going for companies that have already products that are on market and making profit .
Last week following the interims the share price sunk to 2.9p/£4m mcap as they revealed the cash situation and need to raise in the immediate term.
If GDR is a target then it would be savvy to offer 7.1p/£10m for the company with acceptance of offer entirely dependent on whether they manage to raise successfully during April.
As we speak the SP has already dropped below 7p.
GDR Market capitalisation: £10.56 million.
Would JW want to go for 25% when he can have 100%?
I'm not saying he's interested, I just think he might see value in a T/O.
Particularly at this time, as he knows what the situation is re DHSC caving in, or meeting their destiny in court 2 months hence.
Under Mr mullis gdr maybe have been a target >>>>dire.ction ..change ..
All eyes on GDR though as it's a very interesting situation given the recent news. They've already stated a week ago that there's just one more month of cash (May) and will raise soon in what is one of the toughest funding environments in a decade or so...
Despite the positive news it's hard to imagine they'll pull off anything better than a 7p placing.
Yes HC , that s exactly what I meant.
You mean, like, offer all the funding GDR needs at market rate, preventing GDR from the inevitable protracted discounted placing that's coming? £3m at 7p a share would give NCYT a 25% stake in the company (after dilution) and would build a partnership that could be beneficial to us in the future.
I'd be pro this approach alongside acquisitions.
Congratulations to GDR , sounds impressive , was thinking of buying a few but CEO has stated he will raise within a few weeks.
My point of posting is to question if Yourgene are involved in anyway or if Joanne Mason is just liking various posts because of the type of test it is and where the testing is being conducted.
Wonder how a cash rich company could assist 🤔
😁
With all these job vacancies at Yourgene i hope HR have taken on board the recommendations from the CQC.
Thank you Kaeren, I appreciate that info.
Hi Urraca , as far as we are aware, the June date still stands. The general consensus with LTH 's is a settlement agreed prior to June.
If there was any delay to the court date then they would have to issue an RNS ... which have been in short supply, to put it mildly!
Compared to many aim companies NCYT stands out because of its current cash position and we are all acutely aware of the plethora of companies who have struggled to raise and have consequently had to do so at ridiculous prices causing mass dilution.
It remains high risk .. but high gain potential also.
I still believe if it actually gets to court that Ncyt will win.
I haven't been phased by the leavers , except Paul Oladimeji and I personally don't think that was case related , think it was to do with the acquisition of Yourgene and the very different mgt style. Novacyt would have us believe that they 'run the show' looking at Yourgenes ex CEO and our interim CEO , I'm not so sure. I think he will give them all a wake up call, including Wakefield. Is that a good thing ? remains to be seen.
Think the shareholders have been treated appallingly, par for the course with aim.
No reason whatsoever imo that they couldn't make clear what their intentions are regarding a permanent CEO. If we win x will happen, if we lose then x will happen.
As to what R&D are working on , Gawd only knows, I certainly don't!
The information train stopped with GM's departure and we were fed a load of b/s about 100mm target , wasted time and money on a CEO who didn't cut the mustard and have never been proffered any form of explanation as to why he left or why the numbers ( approved by the CFO, now interim CEO) were so wildly inaccurate.
This is the last roll of the dice for me with Novacyt , I am more than fed up !
I still hold because I think we will win and that is the only reason. To even entertain not selling out the inf needs to start flowing and they need to crank up the RNS machine.
Hi guys. Not been in NCYT for quite a while now, but thought it was worth a look. Will the dispute with DHSC finally be put to bed in June? Can’t find any info about it in the RNSs for the past year. It does look pretty undervalued here, especially compared to some others that don’t even have any income.
This is excellent to see.
Let’s not forget that Novacyt’s current valuation is roughly equivalent to just the two largest acquisitions - Primer design and Yourgene. Everything else (including £44m cash) comes for free, assuming a neutral outcome from the dispute.
Only a big loss in the dispute will make Novacyt look fairly valued come June
Hi Larry Tks I'm posting your LinkedIn post from twitter as it makes more sense to the likes of me, seems they've been busy and now telling us
https://twitter.com/larry64450205/status/1773317174414741560/photo/2
Happy Easter all.